Frequently Asked Questions

FidoCure® is the first and only service to bring the same type of targeted medicine we use to treat cancer in humans to canine cancer care.

FidoCure® provides DNA testing to help identify the genetic markers in each case. Using that information, we create a report with recommended targeted therapies and enable access to targeted medicine through our network of partner compounding pharmacies. If the veterinarian determines that the suggested therapy is appropriate for their patient, these therapies are accessible through FidoCure®.
FidoCure® is covered by most insurance companies. Pet parents should check with their insurance company before beginning treatment.
FidoCure® invoices veterinarians separately for the test and therapy. However, the cost for pet parents may differ based on the veterinarians and their clinic fees. We recommend consulting with your veterinarian to obtain an estimate of their rates.
We currently have veterinarian relationships in 32 states and are quickly expanding our pawprint.

Are you a veterinarian? Contact us to find out how you can join the growing FidoCure veterinarian network.
FidoCure® works with veterinarians to treat all cancers. The largest number of our cases have been hemangiosarcoma. We also have significant experience in bladder cancer (TCC) and some rare canine cancers, such as histiocytic sarcoma. Approximately half of our cases were brought to us after their cancer did not respond to traditional therapies.
Once we receive sample tissue from the treating veterinarian, it will take approximately 2 to 3 weeks to complete genetic testing.
Traditionally, veterinarians have relied on a limited scope of treatment options depending on a general diagnosis of which type of cancer a canine has. FidoCure® enables veterinarians to apply targeted therapy to each canine based on their individual case and the unique genetic markers that apply. Targeted medicine, or precision medicine, addresses the issue that there is no one-size-fits-all when it comes to cancer treatment.

FidoCure® genetic testing aims to identify the specific mutations driving each patient’s cancer. Armed with specific information about the patient’s disease and an expanded set of therapeutic options, veterinarians receive a more versatile set of tools to treat their patient.
According to the National Cancer Institute:
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the progression of the disease. Targeted therapies differ from standard chemotherapy in several ways:
  • Targeted therapies can act on specific molecular targets that are associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells
  • Targeted therapies are deliberately chosen or designed to interact with their target, whereas many standard chemotherapies were identified because they kill cells
  • Targeted therapies can have tumor-specific cytotoxic and cytostatic effects (that is, they can be lethal or simply halt tumor cell proliferation), whereas standard chemotherapy agents are cytotoxic (that is, they kill tumor cells and dividing normal cells alike)
  • The veterinarian is in the best position to determine what treatment plan is right for a patient.
Targeted therapy is intended for patients whose tumor has a specific gene mutation that can be mapped to a precise therapy. They can also be used for patients whose cancer did not respond to other therapies, has spread, or is inoperable. Learn more on the National Cancer Institute website.
The Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) allows veterinarians to prescribe drugs that are FDA-approved for humans as targeted therapies for animals as extra-label use. Even conventional therapies, such as chemotherapy, have not been approved for animals by the FDA Center for Veterinary Medicine, so FidoCure®’s recommended therapies fall under the same FDA umbrella. As with any other drug, there are inherent risks and side effects that need to be considered in light of the patient’s overall health. For more information about our toxicity data and dosage criteria, please schedule an appointment with one of our experts. However, when you sign on with FidoCure®, we guarantee:
  • We have a team of world-leading canine cancer experts who have treated thousands of dogs with cancer to ensure we deliver informed, high-quality service.
  • To ensure the validity of our genetic tests, tissue samples have to pass quality assurance and quality control.
  • The dosages we suggest are based on known canine safety and toxicology profiles.
  • We use a reputable compounding pharmacy to ensure the quality of the therapeutics.
All of FidoCure® facilitated targeted therapies are prepared in licensed and Board of Pharmacy inspected facilities under rigorous quality standards and regulations. All therapies are compounded from human-grade active pharmaceutical ingredients (APIs) that are sourced from FDA-registered repackagers of active pharmaceutical ingredients.
Once we receive the diagnostic results, we provide veterinarians with a comprehensive report including recommended therapies. The veterinarian can choose to order a targeted therapy from a designated compounding pharmacy that is experienced with tailoring human therapeutics for canines. It typically takes 3 to 5 business days for therapies to be compounded and shipped once they have been ordered through our partner compounding pharmacy.